Biotech | November 08, 2021
Meiji Seika Pharma to build new facility in Bangalore to expand CMO business
The new manufacturing facility will be built at a subsidiary of Adcock Ingram and will commence operation in March 23
The new manufacturing facility will be built at a subsidiary of Adcock Ingram and will commence operation in March 23
The test kit uses a reagent developed using Kaneka's molecular testing-related technologies
The transaction is anticipated to close in the first quarter of 2022
This is Enzene Biosciences third biosimilar to be approved
Sputnik V is a two-dose shot and has an efficacy of 91.6% against COVID 19
Vikas Lifecare has already paid Rs. 25 million to the Advik bankers till date and the remaining amount shall also be paid within July 2021, making Advik a debt free company
This investment is being made to set up a high speed 400 vials a minute injectable fill line with isolator technology
Cadila's ZyCov-D (DNA-based vaccine) is undergoing phase III trials.
It is expected that the drug substance would be available from August 2021 which will be supplied back to Bharat Biotech for producing COVAXIN
The facility is expected to be completed in 2024
Subscribe To Our Newsletter & Stay Updated
